Melatonin Supplementation in Patients with Complete Tetraplegia and Poor Sleep

Table 2

Sleep study findings recorded at baseline (the night before commencing melatonin supplementation) and on last night of two-week melatonin supplementation period.

	Baseline	Melatonin Supplementation
AI	6.2 (3.8–22.5)	5.8 (3.3–33.5)
AHI	7.6 (3.6–57.7)	3.5 (1.2–48.6)
Stage 1%	1.3 (0–4.4)	2.2 (1.7–2.9)
Stage 2%	45.9 (32.7–68.7)	61.3 (40–68.5)
Stage 3%	15.8 (4.1–35.1)	19 (3.4–32.3)
Stage 4%	14.6 (0–30)	10.9 (0–13.4)
Stage REM%	13.1 (7.8–36.1)	14.2 (10.8–25.2)
REM latency	92 (63.5–169.5)	152.5 (66.5–213.5)
TST	332.5 (90–353.5)	338.5 (292–365)
SpO2 < 90%	0.6 (0–37.6)	0.8 (0.4–21.1)
# Awake times	7 (4–24)	7 (4–40)
Time spent awake	16 (6–149)	20 (5–136.5)

Note: values are median (range). AI (Arousal Index) = number of arousals per hour of sleep; AHI (Apnoea/Hypopnoea Index) = number of apnoeas/hypopnoeas per hour of sleep; TST (Total Sleep Time) = minutes sleep; Time spent awake = minutes spent awake during night after first falling asleep. No statistically significant differences were observed between the baseline and melatonin supplementation sleep study parameters.